AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Avmapki Fakzynja Co-pack (copackaged), and when can generic versions of Avmapki Fakzynja Co-pack (copackaged) launch?
Avmapki Fakzynja Co-pack (copackaged) is a drug marketed by Verastem Inc and is included in one NDA. There are seven patents protecting this drug.
This drug has one hundred and twenty-five patent family members in forty-five countries.
The generic ingredient in AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) is avutometinib potassium; defactinib hydrochloride. One supplier is listed for this compound. Additional details are available on the avutometinib potassium; defactinib hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Avmapki Fakzynja Co-pack (copackaged)
Avmapki Fakzynja Co-pack (copackaged) will be eligible for patent challenges on May 8, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 29, 2042. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)?
- What are the global sales for AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)?
- What is Average Wholesale Price for AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)?
Summary for AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
| International Patents: | 125 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) at DailyMed |
-patent-expirations.png "AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) drug patent expirations")
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
Generic Entry Date for AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE, TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) is protected by eight US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) is ⤷ Start Trial.
This potential generic entry date is based on patent ⤷ Start Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
International Patents for AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
When does loss-of-exclusivity occur for AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 23283699
Patent: SOLID FORMS OF A DUAL RAF/MEK INHIBITOR
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 58080
Patent: FORMES SOLIDES D'UN INHIBITEUR DOUBLE DE RAF/MEK (SOLID FORMS OF A DUAL RAF/MEK INHIBITOR)
Estimated Expiration: ⤷ Start Trial
China
Patent: 0077037
Patent: 双重RAF/MEK抑制剂的固体形式 (Solid forms of dual RAF/MEK inhibitors)
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 36654
Patent: FORMES SOLIDES D'UN INHIBITEUR DOUBLE DE RAF/MEK (SOLID FORMS OF A DUAL RAF/MEK INHIBITOR)
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 25519418
Patent: 二重ＲＡＦ／ＭＥＫ阻害剤の固体形態
Estimated Expiration: ⤷ Start Trial
Mexico
Patent: 24015093
Patent: FORMAS SOLIDAS DE UN INHIBIDOR DUAL DE RAF/MEK (SOLID FORMS OF A DUAL RAF/MEK INHIBITOR)
Estimated Expiration: ⤷ Start Trial
South Korea
Patent: 250020622
Patent: 이중 RAF/MEK 억제제의 고체 형태
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Taiwan | I369205 | ⤷ Start Trial | |
| South Korea | 20080103989 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | ⤷ Start Trial |
| Norway | 20083542 | ⤷ Start Trial | |
| South Korea | 101378634 | ⤷ Start Trial | |
| Brazil | PI0810411 | ⤷ Start Trial | |
| Israel | 232511 | שיטה לייצור תרכובת סולפוניל–אמיד ותרכובות ביניים (Method of making a sulfonyl-amide compound and intermediate compounds thereof) | ⤷ Start Trial |
| Russian Federation | 2008136187 | НОВОЕ ПРОИЗВОДНОЕ КУМАРИНА, ОБЛАДАЮЩЕЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Market Dynamics and Financial Trajectory for AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch